Grupo Espanol De Investigacion En Cancer De Ovario

5 trials 2 recruiting Academic / non-commercial Merged from 2 name variants

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

3 Completed trials

6 Countries active

17 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 1 Phase II: 3 Phase IV: 1

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Breast cancer 1 Endometrial cancer stage III 1 Endometrial cancer stage II 1 Endometrial cancer 1 Cervix carcinoma 1 HER2 positive breast cancer 1

Top IMPs

DOSTARLIMAB 2 ATEZOLIZUMAB 1 BEVACIZUMAB 1 CAPECITABINE 1 CARBOPLATIN 1 DOCETAXEL 1 DOXORUBICIN HYDROCHLORIDE 1 EXEMESTANE 1 FULVESTRANT 1 GEMCITABINE 1 GOSERELIN ACETATE 1 NINTEDANIB 1

All trials

5 total

Phase II clinical trial to assess the efficacy of dostarlimab as neoadjuvant therapy in patients with MMRd/MSI-H stage II-III endometrial ca… Recruiting

2024-512021-81-00 Phase II 1 country DOSTARLIMAB
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Phase IV 1 country CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN HYDROCHLORIDE; EXEMESTANE; FUL…
Trial of dostarlimab (TSR-042) for patients with high-risk locally advanced cervical cancer after chemo-radiation Ended

2023-510268-11-00 Phase II 1 country DOSTARLIMAB
Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients c… Ended

2023-503627-26-00 Phase II 1 country TRASTUZUMAB DERUXTECAN
Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervi… Ended

2024-514179-17-00 Phase III 6 countries ATEZOLIZUMAB; BEVACIZUMAB

Showing 1–5 of 5 trials

← All sponsors A–Z